Page last updated: 2024-09-02

fingolimod hydrochloride and Brain Disorders

fingolimod hydrochloride has been researched along with Brain Disorders in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Altobelli, C; Anastasio, P; Barbarulo, AM; Conchiglia, G; D'Amico, A; Di Pietro, A; Fratta, M; Lus, G; Rossi, F; Signoriello, E; Ugga, L	1
Chara, JC; Cipriani, R; Matute, C; Rodríguez-Antigüedad, A	1
Antel, J; Comi, G; Haas, T; Kappos, L; Karlsson, G; Korn, AA; Montalban, X; O'Connor, P; Polman, CH; Radue, EW	1

Trials

1 trial(s) available for fingolimod hydrochloride and Brain Disorders

Article	Year
Oral fingolimod (FTY720) for relapsing multiple sclerosis. The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11 Topics: Adolescent; Adult; Brain; Brain Diseases; Double-Blind Method; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Respiratory Tract Infections; Sphingosine; Statistics, Nonparametric	2006

Article

Year

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

Topics: Adolescent; Adult; Brain; Brain Diseases; Double-Blind Method; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Respiratory Tract Infections; Sphingosine; Statistics, Nonparametric

2006

Other Studies

2 other study(ies) available for fingolimod hydrochloride and Brain Disorders

Article	Year
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis. Multiple sclerosis and related disorders, 2020, Volume: 38 Topics: Adult; Alemtuzumab; Behavioral Symptoms; Brain Diseases; Brain Stem; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Mutism; Recurrence; White Matter; Young Adult	2020
FTY720 attenuates excitotoxicity and neuroinflammation. Journal of neuroinflammation, 2015, May-08, Volume: 12 Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Brain Diseases; Cell Death; Cells, Cultured; Cerebellum; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Fingolimod Hydrochloride; In Vitro Techniques; Kainic Acid; L-Lactate Dehydrogenase (Cytochrome); Male; N-Methylaspartate; Neurons; Organ Culture Techniques; Phosphorylation; Rats; Rats, Sprague-Dawley; Time Factors	2015

Article

Year

Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.

Multiple sclerosis and related disorders, 2020, Volume: 38

Topics: Adult; Alemtuzumab; Behavioral Symptoms; Brain Diseases; Brain Stem; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Mutism; Recurrence; White Matter; Young Adult

2020

FTY720 attenuates excitotoxicity and neuroinflammation.

Journal of neuroinflammation, 2015, May-08, Volume: 12

Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Brain Diseases; Cell Death; Cells, Cultured; Cerebellum; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Fingolimod Hydrochloride; In Vitro Techniques; Kainic Acid; L-Lactate Dehydrogenase (Cytochrome); Male; N-Methylaspartate; Neurons; Organ Culture Techniques; Phosphorylation; Rats; Rats, Sprague-Dawley; Time Factors

2015